ACRS:NSD-Aclaris Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 22.28

Change

0.00 (0.00)%

Market Cap

USD 1.13B

Volume

0.52M

Average Target Price

USD 25.50 (+14.45%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania. Address: 640 Lee Road, Wayne, PA, United States, 19087

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD61.26B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD55.25B 20.66 14.64
REGN Regeneron Pharmaceuticals, Inc

N/A

USD48.27B 14.76 12.06
ALXN Alexion Pharmaceuticals, Inc

N/A

USD33.58B 56.16 33.22
BGNE BeiGene, Ltd

N/A

USD29.06B N/A N/A
RPRX Royalty Pharma plc

N/A

USD28.27B 22.60 14.17
SGEN Seagen Inc

N/A

USD27.38B 44.84 41.48
BNTX BioNTech SE

N/A

USD26.25B -99,999.99 N/A
GMAB Genmab A/S

N/A

USD22.15B 26.59 3.17
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ACRS

Symbol Name Weight Mer Price(Change) Market Cap
DWMC AdvisorShares Dorsey Wrig.. 0.00 % 1.32 %

N/A

USD2.90M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 244.36% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 244.36% 99% A+ 99% A+
Trailing 12 Months  
Capital Gain 1,854.39% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,854.39% 99% A+ 99% A+
Trailing 5 Years  
Capital Gain 25.80% 54% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.80% 54% F 35% F
Average Annual (5 Year Horizon)  
Capital Gain 23.58% 62% D- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.58% 62% D- 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 250.76% 8% F 5% F
Risk Adjusted Return 9.40% 44% F 38% F
Market Capitalization 1.13B 72% C- 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 27.61 8% F 7% F
Price / Cash Flow Ratio -29.13 80% B- 85% B
EV/EBITDA 0.05 85% B 98% A+
Management Effectiveness  
Return on Equity -95.12% 31% F 12% F
Return on Invested Capital -85.83% 32% F 11% F
Return on Assets -37.64% 31% F 9% F
Debt to Equity Ratio 28.29% 39% F 58% F
Technical Ratios  
Short Ratio 0.21 86% B 85% B
Short Percent 2.99% 75% C 51% F
Beta 0.66 82% B- 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.